
Onxeo announces acquisition of DNA Therapeutics to further develop its cancer treatment options
Under the terms of the agreement, Onxeo is acquiring DNA Therapeutics for an upfront payment of nearly $1.85 million in common shares at deal closing.
Under the terms of the agreement, Onxeo is acquiring DNA Therapeutics for an upfront payment of nearly $1.85 million in common shares at deal closing.